N@N

Market Maker Surveillance Report. AGEN, QTWW, XOMA, DUSA, VRML, EBTX, Winning Stocks With Lowest Price Friction For Tuesday, M

March 6, 2012 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 3395 companies with "abnormal" market making, 1074 companies with positive Friction Factors and 5264 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. AGENUS INC (NASDAQ:AGEN), QUANTUM FUEL SYSTEMS TECHNOL (NASDAQ:QTWW), XOMA LTD (NASDAQ:XOMA), Dusa Pharmaceuticals Inc (NASDAQ:DUSA), VERMILLION INC (NASDAQ:VRML), Encore Bancshares Inc (NASDAQ:EBTX). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     AGEN       $0.550       17.14%       242,627         55.46%       176,986         40.45%       65,641          1,193   
     QTWW       $0.230       25.71%       1,144,667       59.47%       780,268         40.53%       364,399         15,843  
     XOMA       $0.360       24.83%       4,943,896       53.38%       4,168,122       45.00%       775,774         21,549  
     DUSA       $0.700       15.09%       896,016         53.78%       767,589         46.07%       128,427         1,835   
     VRML       $1.740       130.83%      5,779,485       54.19%       4,880,860       45.76%       898,625         5,165   
     EBTX       $5.280       35.41%       863,333         57.13%       645,200         42.70%       218,133         413     

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows AGEN with a dollar gain Tuesday of $0.55000 and a Friction Factor of 1,193 shares. That means that it only took 1,193 more shares of buying than selling to move AGEN higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

AGENUS INC (NASDAQ:AGEN) - Agenus Inc., a biotechnology company, develops and commercializes immunotherapies for cancer and infectious diseases. It markets Oncophage vaccine for the treatment of adjuvant renal cell carcinoma (kidney cancer). The company also has various product candidates under development, which include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of non-small cell lung cancer, melanoma, malaria, and singles, as well as in Phase II clinical trials for the treatment of Alzheimers disease. In addition, the companys product candidates under development comprise Prophage, which is in Phase II clinical trials for the treatment of glioma (brain cancer) and pediatric neurological tumors; and HerpV, which is in Phase I clinical trials for the treatment of genital herpes. Further, it has various other undisclosed vaccines in Phase I and II studies. The company was formerly known as Antigenics Inc. and changed its name in January, 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

QUANTUM FUEL SYSTEMS TECHNOL (NASDAQ:QTWW) - Quantum Fuel Systems Technologies Worldwide, Inc., an integrated alternative energy company, engages in the development and production of propulsion systems, energy storage technologies, and alternative fuel vehicles. Its portfolio of technologies include lithium-ion battery systems, electronic controls, hybrid electric drive and control systems, hydrogen storage and metering systems, and other alternative fuel technologies. The company also engages in powertrain engineering; system integration; manufacturing and assembly of packaged fuel systems; and the provision of battery control systems for vehicles and other applications, including fuel cells, hybrids, plug-in electric hybrid, alternative fuels, and hydrogen refueling stations and systems. Its powertrain engineering, system integration, and assembly capabilities provide fast-to-market solutions to support the production of hybrid and plug-in hybrid, hydrogen-powered hybrid, fuel cell, and alternative fuel vehicles, as well as modular and transportable hydrogen refueling stations. In addition, the company designs, engineers, and manufactures hybrid and fuel cell vehicles. Its customer base includes automotive original equipment manufacturers, military and governmental agencies, aerospace, and other strategic alliance partners. The company operates primarily in the United States, Germany, Iceland, Japan, and Norway. Quantum Fuel Systems Technologies has strategic alliances with General Motors; Fisker Automotive, Inc.; Asola; Advanced Lithium Power, Inc.; Power Control and Design, Inc.; and Shigan Quantum Technologies PVT LTD. The company was founded in 2000 and is headquartered in Irvine, California.

XOMA LTD (NASDAQ:XOMA) - XOMA Ltd., incorporated in 1981, is a biopharmaceutical company in the field of therapeutic antibody discovery and development. The Company has a royalty interest in one approved therapeutic antibody, RAPTIVA, which is marketed in the United States, Europe and elsewhere, for the treatment of moderate-to-severe plaque psoriasis. XOMA also has a future royalty interest in additional therapeutic antibody product candidates being developed by others as a result of licensing its technologies. XOMA's pipeline includes both products and collaborative programs at various stages of preclinical and clinical development primarily directed toward treatments for cancer and immune disorders. In addition to supporting its product pipeline, the Company uses its infrastructure to provide process development and manufacturing services on a fee-for-service basis.

RAPTIVA (Efalizumab)

The Company markets RAPTIVA under an agreement with Genentech, Inc. as a result of a prior collaborative product development program. RAPTIVA is a humanized therapeutic monoclonal antibody developed to treat immune system disorders. RAPTIVA can be self-administered by patients as a single, once-weekly subcutaneous injection. In 2005, Serono had launched RAPTIVA in over 40 countries worldwide.

RAPTIVA competes with Enbrel from Amgen Inc. and its partner Wyeth Pharmaceuticals; Amevive from Biogen Idec Inc.; BG-12 from Biogen Idec Inc. and Fumapharm AG; Remicade from Centocor, Inc. Humira from Abbott Laboratories, and ISA247 from Isotechnika, Inc.

CHIR-12.12

CHIR-12.12, which is being developed by the Company in collaboration with Chiron Corporation, is an anti-CD40 antagonist antibody intended as a treatment for B-cell malignancies. In April 2005, XOMA announced the initiation of Phase I study for patients with advance chronic lymphocytic leukemia (CLL). Then in October 2005, the Company initiated a second Phase I study for patients with multiple myeloma (MM).

NEUPREX (opebacan/rBPI21)

NEUPREX (opebacan/rBPI21) is an injectable formulation of rBPI21, a modified recombinant fragment of human bactericidal/permeability-increasing protein (BPI). BPI is a human host-defense protein made by a type of white blood cell that is involved in the body's defenses against microbial infection. In October of 2003, in conjunction with Children's Medical Center Dallas, the Company announced the initiation of an open-label, single center, dose escalation, investigator-sponsored, Phase I/II clinical trial of NEUPREX in pediatric patients with congenital heart abnormalities requiring open heart surgery associated with cardiopulmonary bypass.

XMA005.2

XMA005.2 is a Human Engineered monoclonal antibody with a high-affinity and potent inhibitory activity against its inflammatory target. This high potency means that it may be suitable for use as a monthly-dose injectable therapeutic. XOMA is evaluating XMA005.2 in preclinical studies targeting multiple indications, including osteoarthritis and rheumatoid arthritis, where less frequent dosing could be a significant marketing advantage.

Anti-gastrin Mab

In September of 2004, XOMA announced a worldwide collaboration with Aphton Corporation to develop treatments for gastrointestinal (GI) and other gastrin-sensitive cancers using anti-gastrin monoclonal antibodies. Gastrin has been shown to be involved in the progression of colorectal, stomach, liver and pancreatic cancers and inhibiting gastrin may inhibit such growth.

Metabolic Disease Target

The Company is co-developing Metabolic Disease Target with Lexicon Genetics. Metabolic Disease Target is a secreted protein involved in metabolic functions such as insulin sensitivity and weight gain that was identified through Lexicon's Knockout Technology. Antibodies to this target may be developed to treat Type II diabetes, obesity and other metabolic diseases.

MLN2222

MLN2222 (also known as CAB2) is being developed by XOMA in partnership with Millennium Pharmaceuticals, Inc. MLN2222 is a complement inhibitor for coronary artery bypass graft surgery tar

Dusa Pharmaceuticals Inc (NASDAQ:DUSA) - DUSA Pharmaceuticals, Inc., a vertically integrated dermatology company, develops and markets Levulan photodynamic therapy (PDT) and other products for common skin conditions in the United States and internationally. Its products include Levulan Kerastick 20% Topical Solution with PDT and the BLU-U brand light source for the treatment of non-hyperkeratotic actinic keratoses of the face or scalp. The company also markets the BLU-U without Levulan for the treatment of moderate inflammatory acne vulgaris and general dermatological conditions. It is also developing non-PDT drug products, including Nicomide, Nicomide-T, AVAR products, ClindaReach, Meted, and Psoriacap. The company was founded in 1991 and is based in Wilmington, Massachusetts.

VERMILLION INC (NASDAQ:VRML) - Vermillion, Inc. and its subsidiaries engage in the discovery, development, and commercialization of diagnostics tests that help physicians to diagnose and treat patients. The company develops novel diagnostic tests in the fields of oncology, hematology, cardiology, and womens health with the initial focus on ovarian cancer. Its lead product includes the OVA1 ovarian tumor triage test (the OVA1 Test), which addresses presurgical identification of women who are at high risk of having a malignant ovarian tumor. The company has collaborations with various academic and research institutions, including The Johns Hopkins University School of Medicine; The University of Texas M.D. Anderson Cancer Center; University College London; The University of Texas Medical Branch; The Katholieke Universiteit Leuven; Clinic of Gynecology and Clinic of Oncology, Rigshospitalet; Copenhagen University Hospital; The Ohio State University Research Foundation; Stanford University; and the University of Kentucky. It also has strategic alliance agreement with Quest Diagnostics Incorporated to develop and commercialize up to three diagnostic tests. Vermillion, Inc. primarily serves clinical reference laboratories. The company was formerly known as Ciphergen Biosystems, Inc. and changed its name to Vermillion, Inc. in August 2007. Vermillion, Inc. was founded in 1993 and is based in Fremont, California.

Encore Bancshares Inc (NASDAQ:EBTX) - Encore Bancshares, Inc. operates as a holding company for the Encore Bank, which provides banking, investment management, financial planning, and insurance services to privately owned businesses, professional firms, investors, and individuals. The companys deposit products and services include checking, savings, money market, and individual retirement accounts, as well as time deposits. Its loan product line for businesses include commercial loans, commercial real estate loans, real estate construction loans, revolving lines of credit, working capital loans, equipment financing, and letters of credit; and for individuals comprise residential mortgage loans, mortgage loans on investment and vacation properties, unsecured and secured personal lines of credit, home equity lines of credit, and overdraft protection. The company also offers personal financial planning services, such as asset preservation/protection, employee benefits, estate planning, investments and asset allocation, retirement planning, risk management, and insurance and tax planning, as well as other financial planning for specific situations. In addition, it provides financial services for businesses through financial counseling for employees, financial planning for executives, and financial workshops for employees. Further, the company offers investment consulting services to individuals, companies, and qualified retirement plans. Additionally, it sells personal and commercial property, and casualty insurance products, as well as provides personal trust services to individuals. The company operates 11 private client offices in Houston, 6 private client offices in southwest Florida, 5 wealth management offices, and 3 insurance offices in Texas. Encore Bancshares, Inc. was founded in 1928 and is headquartered in Houston, Texas.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net